This is a template remove this box before submission

Everything in yellow must be completed as applicable for the trial

Everything in green must be deleted/amended as appropriate

Remember placebo is an IMP!!!

DEVELOPMENT SAFETY UPDATE REPORT

**SHORT TRIAL TITLE**

LONG TRIAL TITLE

Period Covered: XXX – XXX

Document Date: XXX

DSUR number: XXX

MHRA anniversary date of approval: XXX

|  |  |
| --- | --- |
| Chief Investigator: | Insert |
| Sponsor: | Insert |
| Sponsor Reference: | Insert |
| Public Database Number: | Insert |
| CTA Number: | Insert |
| REC Reference: | Insert |

|  |  |  |
| --- | --- | --- |
| **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_****Chief Investigator** | **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_****Signature** | **\_\_\_ \_\_\_ / \_\_\_ \_\_\_ \_\_ / \_\_ \_\_****Date** |

*This Development Safety Update Report contains confidential information and should not be distributed without consent from the Chief Investigator.*

**EXECUTIVE SUMMARY**

CI to provide brief summary of this DSUR

**CONTENTS**

[1. Introduction 3](#_Toc296077464)

[2. Worldwide Marketing Authorisation Status 3](#_Toc296077465)

[3. Actions taken in the reporting period for safety reasons 3](#_Toc296077466)

[4. Changes to reference safety information 3](#_Toc296077467)

[5. Inventory of clinical trials ongoing and completed during the reporting period 3](#_Toc296077468)

[6. Estimated cumulative exposure 4](#_Toc296077469)

[a. Cumulative subject exposure in the development program 4](#_Toc296077470)

[b. Patient exposure from marketing experience 4](#_Toc296077471)

[7. Data in line listings and summary tabulations 5](#_Toc296077472)

[a. Reference information 5](#_Toc296077473)

[b. Line listing of Serious Adverse Reactions (SARs) during reporting period 5](#_Toc296077474)

[c. Cumulative line listings of Serious Adverse Events (SAEs) 5](#_Toc296077475)

[8. Significant findings from clinical trials during reporting period 6](#_Toc296077476)

[a. Completed clinical trials 6](#_Toc296077477)

[b. Ongoing clinical trials 6](#_Toc296077478)

[c. Long term follow-up 6](#_Toc296077479)

[d. Other therapeutic use of IMP 6](#_Toc296077480)

[e. New safety data related to combination therapies 6](#_Toc296077481)

[9. Safety findings from non-interventional studies 6](#_Toc296077482)

[10. Other clinical trial/study safety information 6](#_Toc296077483)

[11. Safety findings from marketing experience 6](#_Toc296077484)

[12. Non clinical data 6](#_Toc296077485)

[13. Literature 7](#_Toc296077486)

[14. Other DSURs 7](#_Toc296077487)

[15. Lack of efficacy 7](#_Toc296077488)

[16. Region specific information 7](#_Toc296077489)

[17. Late breaking information 7](#_Toc296077490)

[18. Overall safety assessment 7](#_Toc296077491)

[a. Evaluation of the risks 7](#_Toc296077492)

[b. Benefit-risk considerations 7](#_Toc296077493)

[19. Summary of important risks 7](#_Toc296077494)

[20. Conclusions 7](#_Toc296077495)

1. **Introduction**

This is the 1st/2nd etc Development Safety Update Report (DSUR) for Full Study Title.

We have provided a copy of this report to the manufacturer(s) and supplier(s) of IMPs name.

1. **Worldwide Marketing Authorisation Status**

For IMPs where a SmPC was submitted : the Marketing Authorisation number (MA) is available on the front of the SmPC – insert information and ensure it is checked by appropriate pharmacist.

Insert IMP name & MA number

For IMPs where a full IMPD/IB was submitted: IMP name is supplied by IMP Supplier who manufacture the IMP in accordance with their MA (IMP), insert MIA (IMP) number

1. **Actions taken in the reporting period for safety reasons during the reporting period**

 The following amendments have been made to this trial:

|  |  |  |  |
| --- | --- | --- | --- |
| **Amendment Number** | **Amendment Date**  | **Summary of Amendment**  | **Reason for amendment** |
|  |  |  |  |
| Only include details of substantial amendments for safety reasons ( please note this includes amendments submitted following Urgent Safety Measures) |

1. **Changes to reference safety information**

Include details of updates to safety section of the SmPc/ IB (version X dated X) within this reporting period

1. **Inventory of clinical trials ongoing and completed during the reporting period**

This DSUR covers a single study: “study title”.

The primary objectives of this study are to assess: insert details

This study is being conducted at X sites, as listed below:

* List of sites

This study plans to enrol X adult patients to receive insert details of treatment.

Study status:

|  |  |
| --- | --- |
| First Patient First Visit: | Date |
| Number of patients screened: | No |
| Number of patients recruited: | No |
| Expected closed to recruitment date: | Date |

Sponsor name does not sponsor any other clinical trials with the same IMP (please contact JRMO for this information).

OR:

Sponsor name also sponsors the following trials with the same IMP(s):

|  |  |  |
| --- | --- | --- |
| **Public Database Number** | **Study Title** | **IMP in common** (if more than one IMP in your trial) |
|  |  |  |

These trials will submit separate DSURs at appropriate time points.

1. **Estimated cumulative exposure**
	1. Cumulative subject exposure in the development program

For open label studies:

X subjects have been exposed to IMP name. Demographic data is as follows:

|  |
| --- |
| Sex:Male: X % Female X% |
| Age:Insert details of age demographics as applicable – i.e. if no upper limit % over 65 years and under |
| Race: |
| Caucasian: X% etc for all races identified |

If trial is randomised repeat for each arm/IMP.

For blinded studies:

This study remains blinded, and the number of subjects exposed is based on the randomisation scheme. Therefore, exposure per treatment cannot be provided.

Given that the trial remains blinded we cannot provide demographic data by treatment group. For the study as a whole:

|  |
| --- |
| Sex:Male: X % Female X% |
| Age:Insert details of age demographics as applicable – i.e. if no upper limit % over 65 years and under |
| Race: |
| Caucasian: X% etc for all races identified |

* 1. Patient exposure from marketing experience

Not applicable, trial is an Investigator-Led study; please refer to MA holder’s DSURs.

1. **Data in line listings and summary tabulations**
	1. Reference information

The Investigator’s Brochure / SmPC (version X dated X) served as the reference point for determination for ‘expectedness’ of all adverse events. Repeat for each IMP

* 1. Line listing of Serious Adverse Reactions (SARs) during reporting period

NB: List all changes in Reference safety Information during the reporting period, section 7b will need to be duplicated, to ensure a line listing exist for each RSI version with this reporting period.

The following Serious Adverse Reactions have occurred during this reporting period:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case Ref No.** | **Subject ID** | **Body System** | **Country** | **Date of Birth** | **Sex** | **IMP Causality** | **Daily dose** | **Dosage form** | **Route of admin.** | **Date of onset** | **Dates of treatment** | **Description (as reported)** | **Outcome** | **Expected** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

* 1. Cumulative line listings of Serious Adverse Events (SAEs)

The following table summarises Serious Adverse Events by System Organ Class (SOC) for the duration of the trial to date:

For single arm open label studies: - see example below

|  |  |  |
| --- | --- | --- |
| **Body system**  |  | **No. Reports** |
| **Blood and Lymphatic Disorders:**Febrile Neutropenia*Total for this system* |  |
| **Cardiac Disorders:**Heart Failure*Total for this system* |  |
| **TOTAL** |  |

For blinded studies: - See example below

|  |  |  |  |
| --- | --- | --- | --- |
| **Body system**  |  | **No. Reports** | **Code Broken** |
| **Blood and Lymphatic Disorders:** Haemolysis Febrile Neutropenia*Total for this system* |  |  |
| **Cardiac Disorders:**Heart Failure*Total for this system* |  |  |
| **TOAL** |  |  |

* 1. Cumulative line listings of SUSARs

The following table summarises Serious Adverse Events by System Organ Class (SOC) for the duration of the trial to date:

For single arm open label studies: - see example below

|  |  |  |
| --- | --- | --- |
| **Body system**  |  | **No. Reports** |
| **Blood and Lymphatic Disorders:**Febrile Neutropenia*Total for this system* |  |
| **Cardiac Disorders:**Heart Failure*Total for this system* |  |
| **TOTAL** |  |

For blinded studies: - See example below

|  |  |  |  |
| --- | --- | --- | --- |
| **Body system**  |  | **No. Reports** | **Code Broken** |
| **Blood and Lymphatic Disorders:** Haemolysis Febrile Neutropenia*Total for this system* |  |  |
| **Cardiac Disorders:**Heart Failure*Total for this system* |  |  |

1. **Significant findings from clinical trials during reporting period**
	1. Completed clinical trials

Not applicable, this DSUR applies to this study only.

* 1. Ongoing clinical trials

This DSUR applies to this study only.

Insert details of findings/concerns etc

OR

DSMB (Data Safety Management Board, or equivalent committee) found no significant findings

OR (if no DSMB)

There are no significant findings to date

Additionally if the CI is aware of clinically important information that has arisen from ongoing clinical trials (e.g., learned through interim safety analyses or as a result of unblinding of subjects with adverse events), this section should briefly summarise the issue(s). It could include information that supports or refutes previously identified safety issues, as well as evidence of new safety signals.

* 1. Long term follow-up

Not applicable, this DSUR applies to this study only.

* 1. Other therapeutic use of IMP

Not applicable, this DSUR applies to this study only.

* 1. New safety data related to combination therapies

If this trial is a combination trial the CI is to provide statement here.

This DSUR applies to this study only.

OR:

Not applicable, this DSUR applies to this study only.

1. **Safety findings from non-interventional studies**

Not applicable, this DSUR applies to this study only.

1. **Other clinical trial/study safety information**

Not applicable, this DSUR applies to this study only.

1. **Safety findings from marketing experience**

Not applicable, this DSUR applies to this study only; trial is an Investigator-Led study; please refer to MA holder’s DSURs.

1. **Non clinical data**

Not applicable, this DSUR applies to this study only; trial is an Investigator-Led study; please refer to MA holder’s DSURs.

1. **Literature**

List any publications that have been published, or come to the attention of the CI during the reporting period regarding the IMP/s in this setting and if these included any safety issues in particular

1. **Other DSURs**

The sponsor will be submitting separate DSURs for the trials listed in Section 5.

OR

Sponsor name does not sponsor any other clinical trials with this/these IMPs

1. **Lack of efficacy**

Not applicable

1. **Region specific information**

Not applicable. Not required by UK regulations.

1. **Late breaking information**

No relevant information was received subsequently to the data-lock for this DSUR.

OR

insert here information received after the DSUR data-lock

1. **Overall safety assessment**
	1. Evaluation of the risks

CI to provide statement (or a statement that there benefit-risk considerations have not changed)

* 1. Benefit-risk considerations

CI to provide statement (or a statement that there benefit-risk considerations have not changed)

1. **Summary of important risks**

CI to provide statement per risk identified in IB, by manufacturers, at trial design stage etc, an example is given below:

***Renal Toxicity:*** *E.g. Dovitinib has been associated with renal toxicities in subjects with ........... To date no renal toxicity has been observed in our population. Subjects are monitored with GGT blood tests fortnightly.*

1. **Conclusions**

If no new risks are identified:

The risks remain consistent with the experience described in our previous ASR/DSUR, and we conclude that the information obtained in this reporting period justifies continuation of the study, with the modifications noted in this DSUR.

If new risks identified:

CI to provide statement